Kezar Life Sciences, Inc. (KZR), a biotech company developing treatments for immune-mediated and oncologic disorders, has launched a restructuring program to focus on its clinical-stage programs and extend its cash runway into late 2026. The company expects to achieve important data readouts for its lead candidates zetomipzomib and KZR-261 in lupus nephritis, autoimmune hepatitis and…